LGND vs CGON
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
LGND · Ligand Pharmaceuticals$306.20 ▲ 2.41%
CGON · CG Oncology$75.99 ▲ 17.27%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- LGND +46.3%
- CGON +88.9%
Head to head
| Metric | LGND | CGON |
|---|---|---|
| Price | $306.20 | $75.99 |
| Change today | ▲ 2.41% | ▲ 17.27% |
| Market cap | $6.12B | $6.74B |
| Return, 3 months | +3.6% | -0.7% |
| Return, year to date | +62.0% | +83.0% |
| Return, 1 year | +51.2% | +91.5% |
| P/E (TTM) | 123.0 | – |
| P/B | 6.4 | 6.8 |
| P/E percentile vs own 5y | 100th | 64th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -31.8% | – |
| Net profit growth (YoY) | -124.3% | -90.8% |
| Gross margin | 95.2% | -85.2% |
| Operating margin | 14.4% | -4,056.2% |
| Net margin | 20.3% | -3,602.7% |
| Return on equity | 5.4% | -26.4% |
| Analyst target vs. price | +19.4% | +21.8% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 50 | 68 |
| 30-day volatility | 39.1% | 63.7% |
| Max drawdown, 1 year | -14.7% | -27.4% |
| Trend read | Leaning bullish | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- CGON is the largest of the group by market value.
- CGON has returned the most over the past year.
- LGND keeps the most profit per dollar of sales.
- LGND has been the calmest stock over the last 30 days.